Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $7.8 million.

  • C4 Therapeutics' Cash from Financing Activities fell 26.01% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year decrease of 82.17%. This contributed to the annual value of $45.3 million for FY2024, which is 0.34% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Cash from Financing Activities is $7.8 million, which was up 16,997.83% from -$46,000 recorded in Q1 2025.
  • C4 Therapeutics' Cash from Financing Activities' 5-year high stood at $170.5 million during Q2 2021, with a 5-year trough of -$10.8 million in Q3 2023.
  • Over the past 3 years, C4 Therapeutics' median Cash from Financing Activities value was $123,500 (recorded in 2024), while the average stood at $9.9 million.
  • Examining YoY changes over the last 5 years, C4 Therapeutics' Cash from Financing Activities showed a top increase of 122,606.38% in 2023 and a maximum decrease of 3,078.67% in 2023.
  • C4 Therapeutics' Cash from Financing Activities (Quarterly) stood at $466,000 in 2021, then slumped by 89.91% to $47,000 in 2022, then spiked by 122,606.38% to $57.7 million in 2023, then slumped by 99.81% to $112,000 in 2024, then decreased by 26.01% to $7.8 million in 2025.
  • Its Cash from Financing Activities was $7.8 million in Q3 2025, compared to -$46,000 in Q1 2025 and $112,000 in Q4 2024.